- The FDA has approved Omeros' (NASDAQ:OMER) investigational new drug application for the company's OMS721 treatment for complementmediated thrombotic microangiopathies (TMAs), which are rare, debilitating and life-threatening disorders characterized by multiple clots in the body's organs, most commonly the kidney and brain.
- The FDA's authorization paves the way for Omeros to start Phase II trials of OMS721, the first one of which is planned for this quarter. (PR)
FDA paves way for Omeros to start Phase II trials of OMS721
Recommended For You
More Trending News
About OMER Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
OMER | - | - |
Omeros Corporation |